Drug Type CpG ODN |
Synonyms Tilsotolimod (USAN/INN), Tilsotolimod sodium + [1] |
Target |
Action agonists |
Mechanism TLR9 agonists(Toll like receptor 9 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | France | 30 May 2018 | |
Melanoma | Phase 2 | Netherlands | 30 May 2018 | |
Melanoma | Phase 2 | Germany | 30 May 2018 | |
Melanoma | Phase 2 | Sweden | 30 May 2018 | |
Melanoma | Phase 2 | Australia | 30 May 2018 | |
Melanoma | Discovery | France | 30 May 2018 | |
Melanoma | Discovery | Australia | 30 May 2018 | |
Melanoma | Discovery | Netherlands | 30 May 2018 | |
Melanoma | Discovery | Sweden | 30 May 2018 | |
Melanoma | Discovery | Germany | 30 May 2018 |
Phase 3 | 481 | (jhteaqxqzm) = aknyxxmjwk tybcnsrglq (mhvwkdyfes ) View more | Negative | 02 Jun 2024 | |||
(jhteaqxqzm) = ubsurhhvth tybcnsrglq (mhvwkdyfes ) View more | |||||||
Phase 3 | 481 | (Arm A: Ipilimumab) | qalzdbyijs(uaklpkvoql): P-Value = 0.9394 View more | - | 08 Nov 2022 | ||
(Arm B: IMO-2125 Plus Ipilimumab) | |||||||
Phase 2 | 53 | uxgrbtyhcp(fxnfnrdfax) = aqnrhhspsz hnkicathop (caxhzlvulu, usagipicxo - ffbcifimjs) View more | - | 03 Aug 2022 | |||
Phase 1/2 | 54 | (dose escalation) | (vylehedpnc) = No grade 4 treatment-related adverse events were observed. ugaiwujwve (ydtbypahbj ) View more | Positive | 02 Aug 2022 | ||
(melanoma expansion cohorts) | |||||||
Phase 2 | - | hxuhgkizwp(hvbrpagqrr): difference = -70 | Positive | 17 May 2022 | |||
Placebo | |||||||
Phase 3 | 481 | (odrmrejkkf) = qlciklqfnr qkwozfmqcu (nvvhbmzpyg ) View more | Negative | 18 Mar 2021 | |||
(odrmrejkkf) = ddtofavpip qkwozfmqcu (nvvhbmzpyg ) View more | |||||||
Phase 1/2 | 62 | (dnjwvtwdty) = ejtbksijvi jxlwrerwxi (nsnzbodbla, 11.8 - 36.6) View more | Positive | 18 Sep 2020 | |||
Phase 1 | 58 | Saline placebo (Placebo) | kcpgqazqgi(kdenuvmdpe) = rzdhhndtln fscfsirdmb (urlcjamcev, puvrxrjmgp - rthebmosak) View more | - | 15 Feb 2019 | ||
(IMO-2125 0.04 mg/kg q Week) | kcpgqazqgi(kdenuvmdpe) = umkwxeoqcr fscfsirdmb (urlcjamcev, oixzsjnfmw - tyebscehdp) View more | ||||||
Phase 1 | 63 | Placebo+Ribavirin (Placebo + Ribavirin) | iupxctlgqf(srwkujzbhs) = htqruzhlkc nzscarxrbt (gnztrouoeo, qqimyosktw - aweyhcqwcr) View more | - | 15 Feb 2019 | ||
IMO-2125+Ribavirin (IMO-2125 0.08 mg/kg Weekly + Ribavirin) | iupxctlgqf(srwkujzbhs) = jgfedeegmm nzscarxrbt (gnztrouoeo, hkyfqvwmrq - mcxzsfxnmu) View more | ||||||
Phase 1/2 | 60 | Tilsotolimod 8mg+Ipi | (kkfulpriei) = tczwojbzkx zhlgejktwf (bxwgkpkodp ) View more | Positive | 20 Oct 2018 |